Sign In
Buy ACAD
$22.60
+0.510 (+2.31%)
At Close: Jun 23, 2026
Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025
09:05am, Thursday, 05'th Jun 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
04:05pm, Thursday, 29'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Mond
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise
04:05pm, Tuesday, 27'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise. In this role All
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 20'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 7, 2025, the Compensation Committee of Acadia's Board of Directors (the “Committee”) granted indu
GSK or ACAD: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 19'th May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attra
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent
10:36am, Monday, 19'th May 2025
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
These Analysts Boost Their Forecasts On Acadia Pharmaceuticals
08:25am, Monday, 19'th May 2025
ACADIA Pharmaceuticals Inc ACAD announced a favorable court ruling on Friday.
Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
10:00am, Saturday, 17'th May 2025
Acadia Pharmaceuticals secured another court win on Nuplazid that solidifies its IP position and long-term exclusivity. The commercial business' performance remains slightly underwhelming but there ar
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation
01:43pm, Friday, 16'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. District Court for the District of Delaware ruled in favor of Acadia regarding its ‘721 formulati
ACADIA Pharmaceuticals: Advancing On Several Fronts
12:01pm, Tuesday, 13'th May 2025
ACADIA Pharmaceuticals posted better-than-expected Q1 results earlier this month. The company has a rock solid balance sheet and advancing a couple of key drug candidates within its pipeline. An updat
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)
07:30pm, Friday, 09'th May 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
11:40am, Thursday, 08'th May 2025
ACAD reports encouraging first-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript
08:10pm, Wednesday, 07'th May 2025
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Al Kildani - SVP of IR & Corporate Communications Catherine Owen Adams - CEO Tom
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates
06:41pm, Wednesday, 07'th May 2025
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.10 per share a year ago.
Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview
04:05pm, Wednesday, 07'th May 2025
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2025. “2025 is off to a strong start for Acadia, ac
